Vertex Pharmaceuticals Unrecognized Tax Benefits Prior Period Decreases remained flat by 0.0% to $1.43M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 200.0%, from $475.00K to $1.43M. Over 2 years (FY 2023 to FY 2025), Unrecognized Tax Benefits Prior Period Decreases shows a downward trend with a -37.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
A decrease is generally positive, indicating that tax risks from prior years are being resolved or mitigated.
This metric tracks the reduction in unrecognized tax benefits related to tax positions taken in prior periods. It reflec...
Standard disclosure for companies resolving historical tax uncertainties.
is_adi_unrecognized_tax_benefits_prior_period_decreases| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $14.40M | $1.90M | $5.70M |
| YoY Change | — | -86.8% | +200.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.